SYNERGY- Everolimus eluting stent with a bioabsorbable polymer in ST elevation myocardial infarction- CLEAR SYNERGY OASIS-9 Registry

Our objective was to evaluate the clinical effectiveness of the SYNERGY stent in patients with ST elevation myocardial infarction (STEMI). The only drug eluting stent approved for treatment of STEMI by the FDA is the Taxus stent which is no longer commercially available, so further data are needed. The CLEAR SYNERGY stent registry was embedded into a larger randomized trial of patients with STEMI (N=7000), comparing colchicine vs. placebo and spironolactone vs. placebo. The primary outcome for the SYNERGY stent registry is major adverse cardiac events (MACE) as defined by cardiovascular death, recurrent MI, or unplanned ischemia driven target vessel revascularization (TVR) within 12 months.

Source: The American Journal of Cardiology - March 3, 2024 Category: Cardiology Authors: Sanjit S. Jolly, Shun Fu Lee, Rajibul Mian, Sasko Kedev, Shahar Lavi, Raul Moreno, Gilles Montalescot, Ali Hillani, Timothy D. Henry, Valon Asani, Robert F. Storey, Johanne Silvain, James C.S. Spratt, Marc-Andr é d'Entremont, Goran Stankovic, Biljana Zaf Source Type: research